Industry: Healthcare Region: France Transaction price: $1 million Transaction method: equity financing
Brief introduction:
Project Is a medical device company dedicated to providing leading technology for the treatment of meibomian gland dysfunction, the most common cause of dry eye disease.
Providing patients with radical remission through innovative therapies (3-4 sessions).
After treatment, 85% of the cases proved to be effective, 96% of the patients recommended product treatment, and 55% of the patients stopped using eye drops after treatment.
Details:
1. Broad market
The global market for xerophthalmopathy, an often overlooked and common disease (which has risen to the second most common eye disease in the world), reached $2.2 billion in 2016 and is expected to reach $5.5 billion by 2020.
2. Technological advantages
Efficient, portable, easy to operate, painless, no side effects, non-invasive, 3 to 4 courses of treatment can be radical (Youfang can only provide palliative treatment), 10 medical patents
3. Financial advantages
With a turnover of 7 million euros in 2019, the company's gross margin of 82% and EBITDA of 49%
4. Sales layout
It has distributed and provided equipment in more than 50 countries/regions around the world, and treated more than 100,000 patients. At the same time, it has the qualification of product access to the Chinese market.